Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The Relief Agreement similarly affords Relief Therapeutics the right to fund the development of ZYESAMI™ for inhaled use. The Relief Agreement provides that in the event Relief Therapeutics chooses not to fund the inhaled use of ZYESAMI™, we would be free to bring in other investment capital for this purpose. Relief Therapeutics has chosen not to fund the inhaled use of ZYESAMI™ and we have proceeded to develop this drug with other sources of capital. Despite Relief Therapeutics’ knowledge that it has not funded these and other areas of the collaboration agreement and despite the non-reproducible nature of the formulation and stability data Relief Therapeutics provided as part of its partnership contribution, Relief Therapeutics continues to advise its shareholders that it is entitled to the previously contemplated share of profits from intravenous and inhaled ZYESAMI™.